A Phase 3 Multicenter, Double-Masked, Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability, and Efficacy of Gildeuretinol Acetate (ALK-001) on the Progression of Stargardt Disease (STGD) - NORTHSTAR
Not yet recruitingCTIS2026-525296-60-00
Alkeus Pharmaceuticals Inc.Stargardt Disease (STGD1)
Target: 43Updated: 2026-08-21